AVEO Pharmaceuticals, Inc.
ANTI-ERBB3 ANTIBODIES
Last updated:
Abstract:
Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
Status:
Application
Type:
Utility
Filling date:
29 Oct 2019
Issue date:
24 Sep 2020